 H.C. Wainwright increased the price target on ATyr Pharma NASDAQ:LIFE to 18 from 13, with the Buy rating unchanged, implying more than 120 upside. Today, the Company reported positive data from a pulmonary sarcoidosis trial evaluating ATYR1923. 